FDA Drug Recalls
1,739 recalls · Class I, newest first
Class I · High risk Ongoing Oct 8, 2025
Reason Marketed Without an Approved NDA/ANDA-FDA analysis revealed undeclared sildenafil (13.1 mg/capsule) and tadalafil (13.8 mg/capsule).
Class I · High risk Ongoing Sep 16, 2025
Reason Subpotent Drug: Testing revealed there was no oxytocin in the IV bag.
Class I · High risk Ongoing Aug 28, 2025
Reason Marketed without an Approved NDA/ANDA: FDA analysis found this product to contain tadalafil
Class I · High risk Ongoing Aug 27, 2025
Reason Labeling: Label Mix Up; Bottles of Meloxicam USP, 7.5mg, 90-count tablets (yellow in color), were labeled as Cyclobenzaprine Hydrochloride Tablets…
Class I · High risk Ongoing Aug 18, 2025
Reason Presence of Particulate Matter.
Class I · High risk Ongoing Aug 18, 2025
Reason Presence of Particulate Matter
Class I · High risk Ongoing Jul 30, 2025
Reason Microbial Contamination of Sterile Products: elevated endotoxin levels
Class I · High risk Ongoing Jul 17, 2025
Reason Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.
Class I · High risk Ongoing Jul 17, 2025
Reason Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.
Class I · High risk Ongoing Jul 17, 2025
Reason Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.
Class I · High risk Ongoing Jul 17, 2025
Reason Microbial Contamination of Non-Sterile Drug Product: The products were found to be contaminated with the bacteria Burkholderia cepecia.
Class I · High risk Ongoing Jun 27, 2025
Reason Labeling: Label Mix-Up; Some vials of Cefazolin for Injection, USP 1 gram were incorrectly labeled as penicillin G potassium for Injection, USP, 20…
Class I · High risk Ongoing Jun 27, 2025
Reason Labeling: Label Mix-Up; cartons of Cefazolin for Injection, USP 1 gram were found to contain vials labeled as penicillin G potassium for Injection…
Class I · High risk Ongoing Jun 6, 2025
Reason Microbial Contamination of Non-Sterile Products: Fungal contamination of infant oral swabs.
Class I · High risk Ongoing Jun 6, 2025
Reason Microbial Contamination of Non-Sterile Products: Fungal contamination of nasal swabs.
Class I · High risk Ongoing Jun 6, 2025
Reason Microbial Contamination of Non-Sterile Products: Fungal contamination of nasal swabs.
Class I · High risk Ongoing Jun 2, 2025
Reason Microbial contamination of non-sterile products: tablets may exhibit black spots due to microbial contamination.
Class I · High risk Completed May 21, 2025
Reason Marketed without approved NDA/ANDA- Laboratory analysis found product to be tainted with undeclared ingredients: Dexamethasone and Diclofenac.
Class I · High risk Completed May 21, 2025
Reason Marketed without approved NDA/ANDA- Laboratory analysis found product to be tainted with undeclared ingredients: Dexamethasone, Diclofenac and…
Class I · High risk Ongoing May 6, 2025
Reason Marketed without approved NDA/ANDA: The product has been found to be tainted with Sildenafil and Propoxyphenylsildenafil (a sildenafil analogue).
Class I · High risk Ongoing Apr 17, 2025
Reason Presence of Particulate Matter
Class I · High risk Ongoing Apr 14, 2025
Reason Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil.
Class I · High risk Ongoing Apr 14, 2025
Reason Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil.
Class I · High risk Ongoing Apr 14, 2025
Reason Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared chloropretadalafil…
Class I · High risk Ongoing Apr 14, 2025
Reason Marketed without an Approved NDA/ANDA: Laboratory analysis found the product to be tainted with undeclared propoxyphenylsildenafil and sildenafil.